A C Vilmar

Summary

Publications

  1. ncbi request reprint Insulin-like Growth Factor Receptor 1 mRNA Expression as a Prognostic Marker in Advanced Non-small Cell Lung Cancer
    Adam Vilmar
    Department of Oncology, Finsen Centre, National University Hospital, Copenhagen, Denmark Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Anticancer Res 34:2991-6. 2014
  2. doi request reprint Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial
    A C Vilmar
    Department of Oncology 5073, Finsen Centre, Copenhagen, Denmark
    Ann Oncol 24:309-14. 2013
  3. doi request reprint RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC
    A Vilmar
    Department of Oncology, Finsen Centre, National University Hospital, Copenhagen, Denmark
    Lung Cancer 75:306-12. 2012
  4. doi request reprint Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature
    Adam Vilmar
    Department of Oncology 5073, Finsen Centre, National University Hospital, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Lung Cancer 64:131-9. 2009
  5. ncbi request reprint [Severe Haemophilus influenzae b infection in healthy male adult]
    Adam C Vilmar
    Onkologisk Klinik, Finsenscenter, Rigshospitalet, DK 2100 København Ø
    Ugeskr Laeger 170:3142-3. 2008
  6. doi request reprint ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial
    A C Vilmar
    Department of Oncology, Finsen Centre, Copenhagen, Denmark
    Ann Oncol 21:1817-24. 2010
  7. doi request reprint ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial
    Adam Vilmar
    Department of Oncology 5073, Finsen Centre, National University Hospital, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Eur J Cancer 46:1554-62. 2010
  8. doi request reprint Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives
    A C Vilmar
    Dept of Oncology, Finsen Centre, National University Hospital, 9 Blegdamsvej, Copenhagen, Denmark
    Eur Respir Rev 20:45-52. 2011
  9. doi request reprint Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial
    Adam Christian Vilmar
    Department of Oncology 5073, Finsen Centre, and Department of Pathology 5442, Diagnostic Center, National University Hospital, Copenhagen, Denmark
    Clin Cancer Res 17:5205-14. 2011

Collaborators

Detail Information

Publications9

  1. ncbi request reprint Insulin-like Growth Factor Receptor 1 mRNA Expression as a Prognostic Marker in Advanced Non-small Cell Lung Cancer
    Adam Vilmar
    Department of Oncology, Finsen Centre, National University Hospital, Copenhagen, Denmark Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Anticancer Res 34:2991-6. 2014
    ..038, respectively). IGF1R protein expression showed a similar, although non-significant tendency. Conclusion: IGF1R mRNA expression may be a prognostic biomarker in advanced NSCLC and should be investigated in a larger population. ..
  2. doi request reprint Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial
    A C Vilmar
    Department of Oncology 5073, Finsen Centre, Copenhagen, Denmark
    Ann Oncol 24:309-14. 2013
    ..A biomarker predicting sensitivity to this antimetabolite would represent a major step forward. Accordingly, we explored the predictive role of ribonucleotide reductase subunit M (RRM1) in advanced NSCLC...
  3. doi request reprint RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC
    A Vilmar
    Department of Oncology, Finsen Centre, National University Hospital, Copenhagen, Denmark
    Lung Cancer 75:306-12. 2012
    ....
  4. doi request reprint Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature
    Adam Vilmar
    Department of Oncology 5073, Finsen Centre, National University Hospital, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Lung Cancer 64:131-9. 2009
    ..Carboplatin has gained widespread use in the treatment of advanced NSCLC and its mechanisms of action are likely similar to that of cisplatin...
  5. ncbi request reprint [Severe Haemophilus influenzae b infection in healthy male adult]
    Adam C Vilmar
    Onkologisk Klinik, Finsenscenter, Rigshospitalet, DK 2100 København Ø
    Ugeskr Laeger 170:3142-3. 2008
    ..We report a case of a healthy 49-year old male with a severe Hib infection complicated by septicaemia, meningitis and anuria. The risk of invasive Hib infections in adults is reviewed...
  6. doi request reprint ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial
    A C Vilmar
    Department of Oncology, Finsen Centre, Copenhagen, Denmark
    Ann Oncol 21:1817-24. 2010
    ..Excision repair cross-complementation group 1 (ERCC1) is a promising biomarker; however, current evidence is inadequate. Impact of ERCC1 status was evaluated among patients participating in a large randomized chemotherapy trial...
  7. doi request reprint ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial
    Adam Vilmar
    Department of Oncology 5073, Finsen Centre, National University Hospital, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Eur J Cancer 46:1554-62. 2010
    ..Excision repair cross complementation group 1 (ERCC1) is a promising biomarker in advanced non-small cell lung cancer (NSCLC). However, current evidence regarding the impact of ERCC1 on toxicity and quality of life (QOL) is limited...
  8. doi request reprint Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives
    A C Vilmar
    Dept of Oncology, Finsen Centre, National University Hospital, 9 Blegdamsvej, Copenhagen, Denmark
    Eur Respir Rev 20:45-52. 2011
    ..Future biomarkers need optimisation of methodology and prospective validation before clinical implementation...
  9. doi request reprint Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial
    Adam Christian Vilmar
    Department of Oncology 5073, Finsen Centre, and Department of Pathology 5442, Diagnostic Center, National University Hospital, Copenhagen, Denmark
    Clin Cancer Res 17:5205-14. 2011
    ..Class III β-tubulin (TUBB3) has been shown of value in NSCLC, but evidence is not uniform. Accordingly, we explored the predictive role of TUBB3 in advanced NSCLC...